<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02661477</url>
  </required_header>
  <id_info>
    <org_study_id>T51/2015</org_study_id>
    <nct_id>NCT02661477</nct_id>
  </id_info>
  <brief_title>Clinical and Virological Efficacy of Pegylated Interferon Alpha in the Treatment of Rhinovirus Infection in Patients With Primary Hypogammaglobulinemia: Randomized Controlled Trial</brief_title>
  <acronym>Hypogamma Int1</acronym>
  <official_title>Clinical and Virological Efficacy of Pegylated Interferon Alpha in the Treatment of Rhinovirus Infection in Patients With Primary Hypogammaglobulinemia: Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will investigate the efficacy and safety of subcutaneous interferon alpha -2a to
      eradicate rhinovirus in patients with primary hypogammaglobulinemia. Patients with
      hypogammaglobulinemia have persistent rhinovirus infections. Rhinovirus may worsen pulmonary
      complications. Pegylated interferon alpha with ribavirin appear to effectively clear
      persistent rhinovirus infections in hypogammaglobulinemia patients.

      Patients with primary hypogammaglobulinemia and confirmed respiratory rhinovirus infection
      will be randomly assigned in a double-blind fashion to receive either

        -  Group 1: subcutaneous pIFNα2a

        -  Group 2: subcutaneous placebo Subjects will have scheduled study visits at 1-week and at
           2-month after entry to study. In addition, possible bacterial infections will be treated
           with antibiotics. Each patient will be followed with weekly nasal surveillance samples
           for 2 months and a symptom diary. Blood draws take place at study entry, 1-week and
           2-month time-points.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of respiratory symptoms</measure>
    <time_frame>within 2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>eradication of rhinovirus from nasal secretion (nasal secretion sample analyzed by rhinovirus PCR)</measure>
    <time_frame>within 2 months (sample taken daily for 7 days, then weekly for 7 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>time to next respiratory infection</measure>
    <time_frame>within 2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of respiratory symptoms</measure>
    <time_frame>2 months</time_frame>
    <description>daily questionnaire for 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rhinovirus genotype-specific persistence</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>2 months</time_frame>
    <description>symptom diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood counts</measure>
    <time_frame>2 months</time_frame>
    <description>at time points 0, 1 wk and 2 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>alanine aminotransferase</measure>
    <time_frame>2 months</time_frame>
    <description>at time points 0, 1 wk and 2 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>creatinine</measure>
    <time_frame>2 months</time_frame>
    <description>at time points 0, 1 wk and 2 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>severity of respiratory functions</measure>
    <time_frame>2 months</time_frame>
    <description>daily questionnaire for 8 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Rhinovirus Infection</condition>
  <arm_group>
    <arm_group_label>pegylated interferon + placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with primary hypogammaglobulinemia and confirmed respiratory rhinovirus infection will receive subcutaneous pIFNα2a (pegylated interferon alfa 2, Pegasys, 180 ug s.c. injection once a week, two times ). Washout period is 8 weeks. When the same patient gets next rhinovirus infection, he/she will receive subcutaneous placebo (0,9% NaCl) injection once a week, two times.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo + pegylated interferon</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with primary hypogammaglobulinemia and confirmed respiratory rhinovirus infection will receive will receivesubcutaneous placebo(0,9% NaCl) injection once a week, two times. Washout period is 8 weeks. When the same patient gets next rhinovirus infection, he/she will subcutaneous pIFNα2a (pegylated interferon alfa 2, Pegasys, 180 ug s.c. injection once a week, two times ).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated interferon alfa 2</intervention_name>
    <arm_group_label>pegylated interferon + placebo</arm_group_label>
    <arm_group_label>placebo + pegylated interferon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0,9% natrium chlorine solution</description>
    <arm_group_label>pegylated interferon + placebo</arm_group_label>
    <arm_group_label>placebo + pegylated interferon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (&gt;18 years),

          -  primary hypogammaglobulinemia with regular immunoglobulin replacement therapy,

          -  rhinovirus positive from nasal swab,

          -  thrombocytes over 90 x109/L,

          -  Neutrophiles &gt; 1,5 x109/L

          -  written informed consent.

        Exclusion Criteria:

          -  Participation to another study,

          -  need for intensive care unit treatment,

          -  difficulties to understand national language, pregnancy and breastfeeding,

          -  any somatic, psychiatric or social disease or issue which in the opinion of the
             investigator makes participation in the trial not being in the best interest of the
             subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tuomas Jartti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turku University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tuomas Jartti, MD</last_name>
    <phone>+358 2 313 0000</phone>
    <email>tuomas.jartti@utu.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Auli Lammela, MD</last_name>
    <phone>+358 2 313 0000</phone>
    <email>auli.lammela@utu.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Turku university hospital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Auli Lammela, MD</last_name>
      <phone>+358 2 313 000</phone>
      <email>auli.lammela@utu.fi</email>
    </contact>
    <investigator>
      <last_name>Auli Lammela, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tuomas Jartti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leena Kainulainen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2016</study_first_submitted>
  <study_first_submitted_qc>January 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2016</study_first_posted>
  <last_update_submitted>April 21, 2016</last_update_submitted>
  <last_update_submitted_qc>April 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Agammaglobulinemia</mesh_term>
    <mesh_term>Common Variable Immunodeficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

